Helicobacter Pylori Testing Market Size & Growth Forecast 2027–2036, By Segments (Test Type, Method, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Helicobacter Pylori Testing Market size was around USD 582.18 million in 2026 and is slated to grow at a 7.53% CAGR from 2027 to 2036, reaching USD 1.2 billion by 2036. The industry revenue for 2027 is assessed at USD 619.38 million.
Get more details on this report
Request Free Sample ReportHelicobacter Pylori Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 37.37% of the market in 2026, supported by advanced diagnostic infrastructure, established healthcare access, and increasing use of non-invasive testing for infection detection and treatment monitoring.
- Asia Pacific is the fastest-growing region as expanding healthcare infrastructure, rising gastrointestinal infection awareness, and greater access to laboratory services increase testing adoption, particularly through non-invasive diagnostics and preventive healthcare initiatives.
Segment Momentum
- Non-invasive testing leads with a 64.32% market share in 2026, supported by patient convenience, greater acceptability, and suitability for initial diagnosis and follow-up monitoring.
- Diagnostic laboratories are the largest and fastest-growing end-use segment, supported by specialized testing infrastructure, standardized processes, diagnostic outsourcing, and demand for reliable infection detection.
Market Expansion Drivers
- Increasing prevalence of gastrointestinal disorders.
- Growing awareness and screening for H. pylori infection.
- Technological advancements in non-invasive diagnostic tests.
Leading Market Participants
- Key players in the helicobacter pylori testing market include Abbott Laboratories (USA), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (USA), Hologic (USA), Bio-Rad Laboratories (USA), DiaSorin (Italy), Meridian Bioscience (USA), Fujirebio (Japan), Sekisui Diagnostics (Japan), QuidelOrtho (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 582.18 million
- 2027 Estimated Market Size: USD 619.38 million
- Projected Market Size: USD 1.2 billion by 2036
- Growth Forecast: 7.53% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Test Type (Non-invasive) | Method (Laboratory Based Tests) | End Use (Diagnostic Labs)
- Emerging Opportunity Segment: Test Type (Non-invasive) | Method (Laboratory Based Tests) | End Use (Diagnostic Labs)
Market Growth Drivers and Industry Trends
Increasing prevalence of gastrointestinal disorders
The increasing prevalence of gastrointestinal disorders is driving demand for helicobacter pylori testing as healthcare providers place greater emphasis on identifying underlying infections associated with digestive conditions. Greater attention to persistent stomach discomfort, ulcers, and related gastrointestinal complications is encouraging diagnostic evaluation and early detection. In addition, improved understanding of the relationship between H. pylori infection and gastrointestinal health is supporting broader use of testing across clinical settings.
Growing awareness and screening for H. pylori infection
Growing awareness of H. pylori infection and its potential impact on gastrointestinal health is encouraging more patients and healthcare professionals to consider screening and diagnostic testing. Increased health awareness is supporting earlier investigation of persistent digestive symptoms and helping identify infections before they contribute to more serious complications. In addition, broader education regarding infection-related risks and the importance of appropriate treatment is contributing to greater acceptance of routine and targeted testing.
Technological advancements in non-invasive diagnostic tests
Technological advancements in non-invasive diagnostic tests are supporting market growth by providing more convenient and patient-friendly approaches to identifying H. pylori infection. Improvements in breath-based, stool-based, and other non-invasive testing methods are helping reduce discomfort associated with diagnostic procedures while supporting efficient clinical assessment. In addition, continued improvements in test accuracy, accessibility, and ease of use are expanding the role of non-invasive diagnostics across healthcare environments.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing prevalence of gastrointestinal disorders | 2.1% | Medium term (2–5 yrs) | Asia Pacific; Europe; North America | Medium | Moderate |
| Growing awareness and screening for H. pylori infection | 1.7% | Short term (≤ 2 yrs) | Asia Pacific; Latin America; MEA | Low | Fast |
| Technological advancements in non-invasive diagnostic tests | 0.9% | Long term (5+ yrs) | North America; Europe; Asia Pacific | Medium | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held a 37.37% share of the helicobacter pylori testing market in 2026, led by advanced diagnostic infrastructure, high healthcare awareness, and widespread access to gastrointestinal disease testing. Growing recognition of the relationship between helicobacter pylori infection and gastrointestinal disorders is encouraging physicians to incorporate appropriate testing into diagnostic and treatment pathways. The availability of non-invasive testing methods, including breath and stool-based approaches, provides convenient options for identifying infection and monitoring treatment outcomes. Established healthcare systems and specialist access further support testing adoption, while increasing emphasis on early diagnosis and preventive healthcare is strengthening demand for reliable diagnostic procedures. Continued improvements in laboratory technologies and greater physician awareness of infection management are also supporting consistent utilization across hospitals, clinics, and diagnostic centers.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region in the helicobacter pylori testing market, influenced by significant healthcare expansion, increasing awareness of gastrointestinal infections, and improving access to diagnostic services. Greater recognition of the health consequences associated with persistent helicobacter pylori infection is encouraging more patients to undergo screening and diagnostic evaluation. Expanding hospital networks, private healthcare facilities, and laboratory services are improving access to testing, particularly in rapidly urbanizing areas. Growing healthcare expenditure and rising awareness of preventive medicine are also supporting the adoption of non-invasive diagnostic techniques that can provide convenient infection detection. Improvements in laboratory capabilities and broader physician education are strengthening diagnostic practices, while the expansion of healthcare services into emerging markets is creating additional opportunities for testing adoption and long-term market development.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Diagnostic AccessibilityIn the U.S., H. pylori testing priorities center on accessible diagnostic pathways and efficient identification of infection across relevant clinical settings. Suppliers can focus on convenient noninvasive testing, reliable laboratory workflows, and integration with routine gastroenterology and primary-care diagnostics to support timely treatment decisions.
Germany 🇩🇪
Clinical Testing IntegrationGermany’s H. pylori testing market is shaped by the need for dependable diagnostics within established healthcare workflows. Commercial priorities include accurate noninvasive testing options, efficient laboratory processing, and solutions that fit gastroenterology and primary-care practices without adding unnecessary complexity to diagnostic pathways.
Japan 🇯🇵
Noninvasive Screening DemandJapan offers a strong clinical use case for convenient H. pylori detection, particularly through noninvasive testing approaches. Market participants can prioritize easy patient sampling, dependable results, and efficient diagnostic workflows, while supporting testing strategies associated with gastrointestinal health management and follow-up care.
South Korea 🇰🇷
Screening-Oriented DiagnosticsSouth Korea’s H. pylori testing market is influenced by the practical need for accessible screening and diagnostic assessment. Suppliers can emphasize noninvasive testing convenience, rapid laboratory workflows, and reliable detection methods that support gastroenterology services and broader clinical programs requiring efficient patient evaluation.
France 🇫🇷
Patient-Friendly DetectionFrance’s market emphasizes practical diagnostic approaches that can improve patient access to H. pylori detection. Noninvasive testing, straightforward sample collection, and dependable laboratory performance are important commercial priorities, particularly where healthcare providers seek efficient diagnostic workflows that can support subsequent clinical management.
Italy 🇮🇹
Gastroenterology Testing DemandItaly’s H. pylori testing market is closely tied to gastrointestinal diagnostic services and the need for reliable infection detection. Suppliers can focus on accessible noninvasive methods, efficient testing workflows, and dependable laboratory support, helping healthcare providers incorporate diagnosis into routine evaluation and follow-up pathways.
Helicobacter Pylori Testing Market Share (%), by Test Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTest Type Segment Analysis: Non-invasive (Largest & Fastest-Growing Segment)
The non-invasive test type segment accounted for a 64.32% share of the market in 2026 and is also expected to grow at the fastest pace, supported by its convenience, patient acceptability, and suitability for routine detection and monitoring of helicobacter pylori infection. Non-invasive testing methods avoid the need for endoscopic procedures and tissue sampling, making them particularly useful for patients who require initial diagnosis or follow-up assessment without undergoing invasive clinical procedures. Their simpler administration can also support broader testing across primary care and diagnostic settings. Increasing awareness of gastrointestinal health, greater emphasis on early detection, and growing preference for patient-friendly diagnostic approaches are supporting demand for non-invasive testing. These methods can also facilitate repeat testing when confirmation of eradication or assessment of treatment outcomes is required. Continued improvements in diagnostic accuracy, ease of sample collection, and accessibility are further strengthening their clinical utility, while healthcare providers increasingly favor approaches that combine reliable detection with improved patient comfort and efficient testing workflows.
Method Segment Analysis: Laboratory Based Tests (Largest & Fastest-Growing Segment)
The laboratory based tests segment represents the largest and fastest-growing method segment in the helicobacter pylori testing market, supported by the importance of centralized diagnostic facilities in delivering standardized and reliable testing services. Laboratory-based approaches can accommodate established diagnostic workflows, quality-control procedures, and professional interpretation, making them valuable for healthcare providers seeking dependable confirmation of infection. Their use across hospitals, diagnostic centers, and specialized testing facilities also supports broad clinical applicability. Growing demand for accurate gastrointestinal diagnostics and increased awareness of helicobacter pylori-associated conditions are contributing to continued laboratory testing activity. Advances in laboratory technologies are improving testing efficiency and enabling healthcare providers to integrate infection detection into broader diagnostic pathways. In addition, the increasing emphasis on evidence-based treatment decisions and confirmation of treatment outcomes is supporting demand for laboratory-based testing. As diagnostic infrastructure expands and testing services become more accessible, laboratory-based methods are expected to retain their strong position while experiencing continued adoption.
End Use Segment Analysis: Diagnostic Labs (Largest & Fastest-Growing Segment)
The diagnostic labs segment represents the largest and fastest-growing end-use segment in the helicobacter pylori testing market, reflecting the central role of specialized laboratories in providing accessible and reliable diagnostic services. Diagnostic laboratories offer dedicated testing infrastructure, trained personnel, and standardized processes that support consistent identification of helicobacter pylori infection. Their ability to handle different sample types and testing methods makes them suitable for both initial diagnosis and follow-up testing. Increasing outsourcing of diagnostic procedures by healthcare providers is also creating opportunities for specialized laboratories, particularly where advanced testing capabilities and efficient turnaround are required. Rising awareness of gastrointestinal infections and the importance of timely diagnosis are further encouraging patients and healthcare professionals to utilize laboratory testing services. Improvements in laboratory automation, digital reporting, and diagnostic workflows are enhancing service efficiency while supporting broader access to testing. As healthcare systems place greater emphasis on accurate diagnosis and preventive management, diagnostic laboratories are expected to remain a key setting for helicobacter pylori testing.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Test Type | Invasive, Non-invasive | Non-invasive | Non-invasive |
| Method | Laboratory Based Tests, Point of Care (POC) Tests | Laboratory Based Tests | Laboratory Based Tests |
| End Use | Diagnostic Labs, Hospitals, Clinics, Others | Diagnostic Labs | Diagnostic Labs |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Success in the Helicobacter pylori testing market relies on balancing clinical accuracy, operational convenience, and broader economic viability. While point-of-care diagnostics must deliver dependable precision without compromising turnaround times or workflow integration, non-invasive breath and stool assays present distinct clinical advantages for initial diagnosis and post-treatment verification. In high-volume central laboratories, automated, high-throughput assays distinguish themselves by optimizing sample turnaround times and seamlessly pairing with existing instrument infrastructure. However, total clinical adoption across all settings ultimately hinges on health economics; favorable reimbursement frameworks, clear cost-effectiveness, and minimal out-of-pocket costs dictate whether testing methods are seamlessly adopted within primary care, specialty facilities, or diagnostic networks.
Key companies in the helicobacter pylori testing market:
- Abbott Laboratories (USA)
- Roche Diagnostics (Switzerland)
- Thermo Fisher Scientific (USA)
- Hologic (USA)
- Bio-Rad Laboratories (USA)
- DiaSorin (Italy)
- Meridian Bioscience (USA)
- Fujirebio (Japan)
- Sekisui Diagnostics (Japan)
- QuidelOrtho (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (USA) | |||||||
| Roche Diagnostics (Switzerland) | |||||||
| Thermo Fisher Scientific (USA) | |||||||
| Hologic (USA) | |||||||
| Bio-Rad Laboratories (USA) | |||||||
| DiaSorin (Italy) | |||||||
| Meridian Bioscience (USA) | |||||||
| Fujirebio (Japan) | |||||||
| Sekisui Diagnostics (Japan) | |||||||
| QuidelOrtho (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Bio-Rad | July 2025 | Bio-Rad launched the Platelia H. Pylori IgG immuno-enzymatic assay, providing a non-invasive and reliable method for the qualitative determination of IgG antibodies to detect H. pylori infections. This commercial introduction expands the company's diagnostic testing capabilities in the infectious disease segment. |
| Biomerica, Inc. | December 2023 | Biomerica, Inc. received U.S. FDA 510(k) clearance for its Hp Detect Stool Antigen ELISA test, a diagnostic tool designed to detect Helicobacter pylori infections and monitor patients post-treatment. This regulatory clearance strengthens the company's market position, enhances competitiveness, and provides medical centers with a reliable means to improve patient management. |
| Meridian Bioscience, Inc. | July 2023 | Meridian Bioscience, Inc. received FDA approval for Premier HpSA FLEX, a non-invasive enzyme immunoassay for diagnosing Helicobacter pylori in preserved and unpreserved stool samples. This approval enhances diagnostic flexibility, broadens the company's product portfolio, and expands its customer base within the gastrointestinal diagnostics segment. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Helicobacter Pylori Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Patient Age Group | Pediatric, Adult, Geriatric |
| Clinical Testing Purpose | Initial Diagnosis, Post-Treatment Confirmation, Recurrence Monitoring |
| Reimbursement Type | Publicly Reimbursed, Privately Reimbursed, Self-Pay |
Helicobacter Pylori Testing Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Screening Program Expansion Strategies |
|
| Diagnostic Pathway Optimization |
|
| Eradication Monitoring Strategies |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the market valuation of the helicobacter pylori testing market?
What is the anticipated CAGR of the helicobacter pylori testing industry?
How is increasing gastrointestinal health awareness influencing H. pylori testing demand?
Why are non-invasive technologies becoming increasingly important in H. pylori diagnostics?
Which test type dominates the Helicobacter pylori testing market?
Which end-use segment is expected to grow fastest?
How does North America's leading position support the Helicobacter pylori testing market?
Why is Asia Pacific emerging as a key growth market for Helicobacter pylori testing?
Which organizations are considered leaders in the helicobacter pylori testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook